|  Help  |  About  |  Contact Us

Publication : The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

First Author  Caswell DR Year  2024
Journal  Nat Genet Volume  56
Issue  1 Pages  60-73
PubMed ID  38049664 Mgi Jnum  J:346208
Mgi Id  MGI:7614935 Doi  10.1038/s41588-023-01592-8
Citation  Caswell DR, et al. (2024) The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nat Genet 56(1):60-73
abstractText  In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-kappaB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

15 Bio Entities

Trail: Publication

0 Expression